Papers I Editorials and Letters to the Editor I Abstract and Poster Sessions I Textbooks I Textbook Chapters

Abstracts and Poster Sessions:

Merrick GS and Kane AB. Colony Formation by Mouse Peritoneal Macrophages Exposed to Asbestos. 1982 FASEB Convention, New Orleans, Louisiana.


Merrick GS, Butler WM, Dorsey AT, Walbert HL. Prostatic Conformal Brachytherapy: I-125/Pd-103 Postoperative Dosimetric Analysis. American Brachytherapy Society Annual Meeting, West Palm Beach, Florida. May 20, 1997.

Merrick GS, Butler WM, Dorsey AT, Walbert HL. Prostatic Conformal Brachytherapy: I-125/Pd-103 Postoperative Dosimetric Analysis. 1997 AAPM Annual Meeting, Milwaukee, Wisconsin. Med Phys 1997; 24(6):963.


Merrick GS, Butler WM, Dorsey AT, Walbert HL. The Influence of Timing on the Dosimetric Analysis of Transperineal Ultrasound-Guided Prostatic Conformal Brachytherapy. J Brachy Int 1998; 14(3):198.

Butler WM, Dorsey AT, Merrick GS. Peripheral vs. Modified Uniform Seed Loading in Prostate Brachytherapy. 1998 AAPM Annual Meeting, San Antonio, Texas. Med Phys 1998; 25(7):A172.

Butler WM, Dorsey AT, Merrick GS. Isotope Choice and the Effect of Edema on Prostate Brachytherapy Dosimetry. 1998 AAPM Annual Meeting, San Antonio, Texas. Med Phys 1998; 25(7):A172.

Merrick GS, Butler WM, Dorsey AT, Walbert HL. The Influence of Timing on the Dosimetric Analysis of Permanent Prostate Brachytherapy. 1998 AAPM Annual Meeting, San Antonio, Texas. Med Phys 1998; 25(7):A93.

Merrick GS, Butler WM, Lief JH, Stipetich RL, Abel LJ, Dorsey AT. The Efficacy of Sildenafil Citrate in Prostate Brachytherapy Patients with Erectile Dysfunction. J Brachy Int 1999; 15(2):144.

Merrick GS, Butler WM, Lief JH, Dorsey AT. The Influence of Prophylactic Dexamethasone on Edema Following Prostate Brachytherapy. J Brachy Int 1999; 15(2):144.

Merrick GS, Butler WM, Lief JH, Dorsey AT. The Dependence of Prostate Post-Implant Dosimetric Quality on CT Volume Determination. J Brachy Int 1999; 15(2):144.

Butler WM, Merrick GS, Lief JH, Dorsey AT. Comparison of Seed Loading Approaches in Prostate Brachytherapy. J Brachy Int 1999; 15(2):138.

Butler WM, Merrick GS, Lief JH, Dorsey AT. Isotope Choice and the Effect of Edema on Prostate Brachytherapy Dosimetry. J Brachy Int 1999; 15(2):138.

Merrick GS, Butler WM, Dorsey AT, Benson ML, Lief JH. Seed Stability in the Prostate/Periprostatic Region Following Brachytherapy. J Brachy Int 1999; 15(2):143.


Butler WM, Merrick GS, Lief JH, Dorsey AT. The Dependence of Prostate Post-implant Dosimetric Quality on CT Volume Determination. Med Phys 1999; 26(6):1145.

Butler WM, Merrick GS, Benson ML, Dorsey AT, Lief JH. Seed Stability in the Prostate/Periprostatic Region Following Brachytherapy. Med Phys 1999; 26(6):1146.

Merrick GS. Transperineal Ultrasound Guided Permanent Prostate Brachytherapy. Int J Radiat Onc Biol Phys 2000; 46:696.

Merrick GS, Butler WM, Dorsey AT, Lief JH. The Influence of Prophylactic Dexamethasone on Edema Following Prostate Brachytherapy. Int J Radiat Onc Biol Phys 2000; 46:765-766.

Merrick GS, Butler WM, Lief JH, Dorsey AT. Temporal Resolution of Urinary Morbidity Following Prostate Brachytherapy. Int J Radiat Onc Biol Phys 2000; 46:763-764.

Merrick GS and Butler WM. Modified Uniform Seed Loading for Prostate Brachytherapy: Rationale, Design and Evaluation. Int J Radiat Onc Biol Phys 2000; 46:746.

Merrick GS, Butler WM, Dorsey AT, Lief JH, Donzella JG. Radiation Dose to the Neurovascular Bundles Following Prostate Brachytherapy. Int J Radiat Onc Biol Phys 2000; 46:763.

Merrick GS, Butler WM, Dorsey AT, Galbreath RW, Blatt H, Lief JH. Rectal Function Following Prostate Brachytherapy. Radiotherapy & Oncology 2000; 55(supp 1):74.

Merrick GS, Butler WM, Dorsey AT, Lief JH, Bhullar S. The Effect of Prostate Size and Isotope Selection on Dosimetric Quality Following Permanent Seed Implantation. Radiotherapy & Oncology 2000; 55(supp 1):75.

Merrick GS, Butler WM, Dorsey AT, Dorsey JT. The Effect of Constipation on Rectal Dosimetry Following Prostate Brachytherapy. Radiotherapy & Oncology 2000; 55(supp 1):90.

Merrick GS, Butler WM, Dorsey AT, Lief JH, Donzella JG. Radiation Dose to the Neurovascular Bundles Following Prostate Brachytherapy. Radiotherapy & Oncology 2000; 55(supp 1):74.

Gray JR, Merrick GS, Beyer DC, Clarke DH, Friedland JL, Fuller DB, Moran BJ, Blasko JC, Sylvester J, Banks SJM, Grimm PD. For the Prostate Brachytherapy Research Group. Comparative Analysis of Prostate Brachytherapy Pre-Planning. Radiotherapy & Oncology 2000; 55(supp 1):42-43.

Merrick GS, Butler WB, Dorsey AT, Galbreath RW, Blatt H, Lief JH. Rectal function following prostate brachytherapy. The Northeastern Section of American Urological Association, Pittsburgh, PA 9/17/2000.

Merrick GS, Butler WM, Galbreath RW, Dorsey AT, Lief JH, Donzella JG. The relationship between transition zone index and urinary morbidity following prostate brachytherapy. The Northeastern Section of American Urological Association, Pittsburgh, PA 9/17/2000.

Merrick GS, Butler WM, Dorsey AT, Lief JH, Donzella JG. A comparison of radiation dose to the neurovascular bundles in men with and without prostate brachytherapy induced erectile dysfunction. The Northeastern Section of American Urological Association, Pittsburgh, PA 9/17/2000.

Merrick GS, Butler WM, Dorsey AT, Lief JH, Bhullar S. The effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation. The Northeastern Section of American Urological Association, Pittsburgh, PA 9/17/2000.

Merrick GS, Butler WM, Lief JH, Dorsey AT. Is brachytherapy comparable with radical prostatectomy and external beam radiation for clinically localized prostate cancer? The Northeastern Section of American Urological Association, Pittsburgh, PA 9/17/2000.

Tollenaar B, Butler W, Merrick G, Galbreath R, Lief J. The dosimetry of prostate brachytherapy-induced urethral strictures. 2001 AAPM Annual Meeting, Salt Lake City, UT. Medical Physics 2001; 28:1279.


Butler W, Merrick G, Galbreath R, Lief J, Benson M. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction. 2001 AAPM Annual Meeting, Salt Lake City, UT. Medical Physics 2001; 28:1281.

Butler W, Merrick G, Burden L, Dougherty J. Extracapsular dose distribution following permanent prostate brachytherapy. 2001 AAPM Annual Meeting, Salt Lake City, UT. Medical Physics 2001; 28:1282.

Merrick GS, Wallner K, Butler WM, Galbreath RW, Lief JH, Benson ML. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy induced erectile dysfunction. 2001 ABS Annual Meeting, Vancouver, BC. J Brachyther Int 2001; 17:93.

Hughes S, Wallner K, Merrick G, Miller S, True L. Pre-existing histologic evidence of prostatitis is unrelated to postimplant urinary morbidity. 2001 ABS Annual Meeting, Vancouver, BC. J Brachyther Int 2001; 17:128.

Merrick GS, Butler WM, Lief JH, Galbreath RW. Five year biochemical outcome after prostate brachytherapy for hormone-naive men 62 years of age or younger. 2001 ABS Annual Meeting, Vancouver, BC. J Brachyther Int 2001; 17:130.

Merrick GS, Butler WM, Tollenaar BG, Galbreath RW, Lief JH. The dosimetry of prostate brachytherapy-induced urethral strictures. 2001 ABS Annual Meeting, Vancouver, BC. J Brachyther Int 2001; 17:131.

Merrick GS, Butler WM, Wallner KE, Burden LR, Dougherty JE. Extracapsular radiation dose distribution following permanent prostate brachytherapy. 2001 ABS Annual Meeting, Vancouver, BC. J Brachyther Int 2001; 17:131

Merrick GS, Butler WM, Galbreath RW, Lief JH. Five year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. 2001 ABS Annual Meeting, Vancouver, BC. J Brachyther Int 2001; 17:132.

Butler WM, Merrick GS, Wallner KE, Burden LR, Dougherty JE. Extracapsular radiation dose distribution following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51(suppl):393.


Tollenaar BG, Merrick GS, Butler WM, Galbreath RW, Lief JH. The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys 2001; 51(suppl):197.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E. The relationship between percent positive biopsies and biochemical outcome following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51(suppl):315.

Galbreath RW, Merrick GS, Butler WM, Stipetich RL, Abel LJ, Lief JH. Sexual function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51(suppl):99.

Ghaly M, Wallner K, Merrick G, True L, Cavanagh W, Butler W. Brachytherapy versus brachytherapy plus beam radiation for prostate cancer: Morbidity outcomes from two prospective randomized multicenter trials. Int J Radiat Oncol Biol Phys 2002; 54(suppl):36.

Anderson RL, Merrick GS, Butler WM, Wallner KE, Galbreath RW. Benign prostate-specific antigen (PSA) spikes following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 54(suppl):40.

Lief JH, Merrick GS, Butler WM, Anderson RL, Smeiles BJ, Benson ML. Correlation between radiation dose to the proximal penis and the development of brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys 2002; 54(suppl):111.

Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW. Prophylactic versus therapeutic alpha blockers in the management of short-term urinary morbidity following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 54(suppl):257.

Adamovich E, Merrick GS, Butler WM, Galbreath RW, Lief JH. Does hormonal manipulation improve biochemical outcome for intermediate or high risk prostate cancer managed with permanent interstitial brachytherapy? Int J Radiat Oncol Biol Phys 2002; 54(suppl):258.


Han BH, Wallner KE, Badiozamani KR, Merrick GS. Differences in prostate volume delineation on post-prostate brachytherapy CT scans among experienced brachytherapists and their effect on dosimetric parameters. Int J Radiat Oncol Biol Phys 2002; 54(suppl):274.

Reed DR, Wallner KE, Merrick GS, Butler WM, Han BH, Sutlief SG, Cho PS. Isodose patterns in patients with inadequate prostate brachytherapy coverage, and its application to intraoperative dosimetry planning. Brachytherapy 2003; 2:49.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH. Long-term urinary quality of life following permanent prostate brachytherapy. Brachytherapy 2003; 2:51-52.

Hoffelt SC, Wallner KE, Merrick G. Epididymitis following prostate brachytherapy. Brachytherapy 2003; 2:64.

Merrick GS, Butler WM, Wallner KE, Murray BC, Allen ZA, Lief JH, Galbreath RW. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy. Brachytherapy 2003; 2:65.

Kurko B, Merrick GS, Butler WM, Wallner KE, Cleavinger S. Rectal function following brachytherapy: Results of two prospective randomized trials. Int J Radiat Oncol Biol Phys 2003; 57(2S):S230.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, and Adamovich E. Biochemical survival for patients with Gleason score 8 and 9 prostate cancer and PSA < 20 following permanent prostate brachytherapy. Med Phys 2003; 30:1467.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B, and Cleavinger S. Rectal function following brachytherapy: Early results of two prospective randomized trials. Med Phys 2003; 30:1466-1467.

Merrick GS, Butler WM, Wallner KE, Hines AL, Allen Z, and Galbreath RW. Long-term rectal function following prostate brachytherapy. Med Phys 2003; 30:1467.

Merrick GS, Butler WM, Wallner KE, Lief JH, Hinerman-Mulroy A, and Galbreath RW. Clinical, treatment, and dosimetric parameters predictive of prostate specific antigen (PSA) spikes following prostate brachytherapy. Med Phys 2003; 30:1467.

Merrick GS, Butler WM, Wallner KE, Murray BC, Allen ZA, Lief JH, and Galbreath RW. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy. Med Phys 2003; 30:1468.

Butler WM, Merrick GS, and Allen ZA. Preimplant dosimetric parameters as predictors of postimplant quality in permanent prostate brachytherapy. Med Phys 2003; 30:1430.

Reed D, Merrick G, Butler W, Wallner K, Galbreath R, Lief J, Adamovich E. Prognostic significance of percent positive biopsies in clinically organ-confined prostate cancer treated with permanent prostate brachytherapy with or without supplemental external beam radiation. Radiother and Oncol 2004; 71(suppl 2):S18.

Reed D, Merrick G, Butler W, Wallner K, Galbreath R, Lief J, Allen Z, Adamovich E. The impact of supplemental external beam radiation and/or androgen deprivation therapy on biochemical outcome following permanent prostate brachytherapy. Radiother and Oncol 2004; 71(suppl 2):S19.

Reed D, Merrick G, Butler W, Wallner K, Allen Z, DeFilippo J, Adamovich E. Enzymatic prostatic acid phosphatase in the clinical staging of patients with newly diagnosed, untreated prostate cancer. Radiother and Oncol 2004; 71(suppl 2):S88.

Reed D, Merrick G, Butler W, Wallner K, Allen Z, Lief J, Hinerman-Mulroy A, Galbreath R. The impact of prostate volume and neoadjuvant androgen deprivation therapy on urinary function following prostate brachytherapy. Radiother and Oncol 2004; 71(suppl 2):S89.

Reed D, Merrick G, Butler W, Wallner K, Galbreath R, Lief J, Adamovich E. Does cigarette smoking influence biochemical outcome following permanent prostate brachytherapy? Radiother and Oncol 2004; 71(suppl 2):S112.

Reed D, Merrick G, Butler W, Wallner K, Galbreath R, Adamovich E. Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA < 20 ng/mL. Radiother and Oncol 2004; 71(suppl 2):S117.

Reed D, Merrick G, Butler W, Wallner K, Galbreath R, Allen Z, Adamovich E. Temporal effect of neoadjuvant androgen deprivation therapy on PSA kinetics following permanent prostate brachytherapy with or without supplemental external beam radiation. Radiother and Oncol 2004; 71(suppl 2):S121.

Reed D, Wallner K, Cho P, Ford E, Merrick G. I-125 isodose patterns as predictors of inadequate prostate brachytherapy dose coverage. Radiother and Oncol 2004; 71(suppl 2):S123.

Reed D, Merrick G, Hinerman-Mulroy A, Butler W, Wallner K, Allen Z, Adamovich E. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity following permanent interstitial brachytherapy. Radiother and Oncol 2004; 71(suppl 2):S127.

Reed D, Merrick G, Butler W, Wallner K, Galbreath R, Adamovich E. Permanent interstitial brachytherapy for younger patients with clinically organ-confined prostate cancer. Radiother and Oncol 2004; 71(suppl 2):S127.

Hinerman-Mulroy A, Butler W, Merrick G, Allen Z, Adamovich E. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity following permanent interstitial brachytherapy. Med Phys 2004; 31:1864.

Allen Z, Butler W, Merrick G, Galbreath R, Adamovich E. Effect of Neoadjuvant androgen deprivation therapy on PSA kinetics following permanent prostate brachytherapy with or without supplemental external beam radiation. Med Phys 2004; 31:1883.

Merrick G, Butler W, Galbreath R, Adamovich E. Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA < 20 ng/mL. Med Phys 2004; 31:1908.

Galbreath R, Merrick G, Butler W, Adamovich E. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Med Phys 2004; 31:1908.


Butler W, Merrick G, Galbreath R, Lief J, Adamovich E. Prognostic significance of percent positive biopsies in prostate cancer treated with permanent prostate brachytherapy with or without supplemental external beam radiation. Med Phys 2004; 31:1910.

Hinerman-Mulroy A, Butler W, Merrick G, Allen Z, Lief J, Galbreath R. The impact of prostate volume and neoadjuvant androgen deprivation therapy on urinary function following prostate brachytherapy. Med Phys 2004; 31:1921.

Anderson RL, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B, Lief JH, Allen ZA. Erectile function following permanent prostate brachytherapy: Results of two prospective randomized trials. Int J Radiat Oncol Biol Phys 2004; 60:S453.

Reed DR, Mueller A, Wallner K, Ford E, Merrick G. RAPID Strand™ vs. loose (Iodine-125 Seeds): A prospective randomized trial. Int J Radiat Oncol Biol Phys 2004; 60:S461.

Merrick G, Butler W, Wallner K, Blasko J, Michalski J, Aronowitz J, Grimm P, Moran B, McLaughlin P, Usher J, Allen Z. Variability of prostate brachytherapy preimplant dosimetry: A multi-institutional analysis. JCO 2005; 23(16suppl):392s.

Allen Z, Merrick G, Butler W, Wallner K, Kurko B, Anderson R, Murray B, Galbreath R. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. JCO 2005; 23(16suppl):430s.

Butler W, Merrick G, Wallner K, Galbreath R, Allen Z, Adamovich E. The impact of primary Gleason grade on biochemical outcome following brachytherapy for Gleason score 7 prostate cancer. JCO 2005; 23(16suppl):427s.

Merrick GS, Butler WM, Wallner KE, Blasko JC, Michalski JM, Aronowitz J, Grimm P, Moran BJ, McLaughlin PW, Usher J, Lief J, Allen ZA. Variability of prostate brachytherapy preimplant dosimetry: A multi-institutional analysis. Brachytherapy 2005; 4:86.

Herstein A, Wallner KE, Merrick GS, Mitsuyama P, Armstrong J, True L, Cavanagh W, Butler WM. I-125 versus Pd-103 for low risk prostate cancer. Morbidity outcomes from a prospective randomized multi-center controlled trial. Brachytherapy 2005; 4:87.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich A. The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone naive Gleason score 7 prostate cancer. Brachytherapy 2005; 4:107.

Allen ZA, Merrick GS, Butler WM, Wallner KE, Kurko B, Anderson RL, Murray BC, Galbreath RW. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Brachytherapy 2005; 4:103.

Beekman M, Merrick GS, Butler WM, Wallner KE, Allen ZA, Gutman S, Usher J, Galbreath RW. Relationship between post-void residual urine and brachytherapy-related urinary morbidity. Brachytherapy 2005; 4:105.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E. Prognostic significance of perineural invasion following prostate brachytherapy. Brachytherapy 2005; 4:101.

Gutman S, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW. Relationship between preimplant international prostate symptom score and urinary morbidity following permanent prostate brachytherapy. Brachytherapy 2005; 4:102.

Niehaus A, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Adamovich E. Relationship between isotope, prostate volume and urinary morbidity following prostate brachytherapy. Brachytherapy 2005; 4:104.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Coram R. Efficacy of neoadjuvant dutasteride and bicalutamide as a cytoreductive regimen prior to permanent interstitial brachytherapy. Brachytherapy 2005; 4:113.

Reed DR, Wallner KE, Ford E, Narayanan S, Merrick G, Orio P, Cho P. Incidence and change over time of adverse isodose pattern in patients undergoing prostate brachytherapy. Brachytherapy 2005; 4:109.

Reed DR, Wallner KE, Ford E, Merrick GS, Butler WM, Narayanan S, Cho P. Effect of post-implant edema on treatment margin measurements after prostate brachytherapy with MRI-based dosimetry. Brachytherapy 2005; 4:104.

Reed DR, Wallner KE, Mueller A, Ford E, Sutlief S, Merrick G, Cho P. Rapid Strand™ vs. loose (Iodine-125 seeds): A prospective randomized trial. Brachytherapy 2005; 4:113.

Herstein A, Wallner KI, Merrick G, Mitsuyama P, Armstrong J, True L, Cavanagh W, Butler W. I-125 versus Pd-103 for low risk prostate cancer: Morbidity outcomes from a prospective randomized multi-center controlled trial. Brachytherapy 2005; 4:87.

Reed DR, Wallner KE, Narayanan S, Merrick GS, Butler WM, Sutlief S, Cho P. Intraoperative fluoroscopic-based dosimetry in prostate brachytherapy patients. Brachytherapy 2005; 4:86.

Allen Z, Merrick G, Butler W, Kurko B, Anderson R, Murray B, Galbreath R. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Med Phys 2005; 32:1955.

Adamovich E, Merrick G, Butler W, Galbreath R, Allen Z. Prognostic significance of perineural invasion on biochemical progression-free survival following prostate brachytherapy. Med Phys 2005; 32:1960.

Galbreath R, Merrick G, Butler W, Anderson R, Allen Z. Prostate brachytherapy-induced urethral strictures. Med Phys 2005; 32:1960.

Butler W, Niehaus A, Merrick G, Allen Z, Galbreath R, Adamovich E. Relationship between isotope, prostate volume and urinary morbidity following prostate brachytherapy. Med Phys 2005; 32:1961.

Galbreath R, Beekman M, Merrick G, Butler W, Allen Z, Gutman S, Usher J. Selecting patients with a pretreatment post-void residual urine < 100 cc may favorably influence brachytherapy-related urinary morbidity. Med Phys 2005; 32:1961.

Merrick G, Butler W, Galbreath R, Allen Z, Adamovich E. The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone naïve Gleason score 7 prostate cancer. Med Phys 2005; 32:1961.

Butler W, Merrick G, Wallner K, Blasko J, Michalski J, Aronowitz J, Grimm P, Moran B, McLaughlin P. Variability of prostate brachytherapy preimplant dosimetry: A multi-institutional analysis. Med Phys 2005; 32:1962.

Orio PF, Wallner K, Merrick G, True L, Sutlief S, Butler W. 20 Gy Versus 44 Gy Supplemental Beam Radiation with Pd-103 Prostate Brachytherapy: Early Biochemical Outcomes From a Prospective Randomized Multi-Center Trial. Int J Radiat Oncol Biol Phys 2005; 63 (2 suppl 1):S289.

Anderson RL, Merrick GS, Butler WM, Wallner KE, Galbreath RW, and Coram R. Efficacy of Neoadjuvant dutasteride and bicalutamide as a cytoreductive regimen prior to permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2005; 63 (2 suppl 1):S299.

Butler WM, Merrick GS, Wallner KE, Galbreath RW, Anderson RL, Allen ZA. Prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys 2005; 63 (2 suppl 1):S299.

Herstein A, Wallner K, Merrick G, Mitsuyama P, Armstrong J, True L, Cavanagh W, and Butler W. I-125 versus Pd-103 for low risk prostate cancer: Morbidity outcomes from a prospective randomized multi-center controlled trial. Int J Radiat Oncol Biol Phys 2005; 63 (2 suppl 1):S317.

Gutman S, Merrick G, Butler W, Wallner K, Allen Z, and Galbreath R. Influence of preimplant International Prostate Symptom Score on urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 63 (2 suppl 1):S322.

Galbreath RW, Merrick G, Butler W, Wallner K, Allen Z, and Adamovich E. Prognostic significance of perineural invasion on biochemical progression-free survival following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 63 (2 suppl 1):S329.

Reed DR, Wallner KE, Ford E, Merrick GS, Sutlief S. Effect of post-implant edema on treatment margin measurements after prostate brachytherapy with MRI-based dosimetry. American Radium Society 88th Annual Meeting, Wailea, HI. May 8, 2006. Oncology 2006; 5:12 (suppl 3).

Reed DR, Wallner KE, Narayanan S, Sutlief S, Cho P, Merrick GS. Intraoperative fluoroscopic dose assessment in prostate brachytherapy patients. American Radium Society 88th Annual Meeting, Wailea, HI. May 10, 2006. Oncology 2006; 5:22 (suppl 3).

Mitsuyama H, Orio PF, Merrick GS, True L, Wallner KE. The prognostic value of tertiary Gleason Pattern 5 in prostate brachytherapy. American Radium Society 88th Annual Meeting, Wailea, HI. May 10, 2006. Oncology 2006; 5:23 (suppl 3).

Reed DR, Wallner KE, Ford E, Merrick GS, Sutlief S, Butler WM. Change in prostate brachytherapy isodose patterns with day 0 and day 30 CT/MR based dosimetry. American Radium Society 88th Annual Meeting, Wailea, HI. May 6-10, 2006. Oncology 2006; 5:32 (suppl 3).

 

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich A. Androgen deprivation therapy does not impact cause-specific or overall survival following permanent prostate brachytherapy. American Brachytherapy Society Annual Meeting, Philadelphia, PA. May 11, 2006. Brachytherapy 2006; 5:86.

Merrick GS, Butler WM, Wallner KE, Allen ZA, Kurko BC, Anderson RL, Grammer R, Galbreath RW. Extracapsular radiation dose annulus correlates with biochemical control in low risk brachytherapy patients: Results of a prospective randomized trial. American Brachytherapy Society Annual Meeting, Philadelphia, PA. May 10, 2006. Brachytherapy 2006; 5:78. 

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Coram R. Efficacy of neoadjuvant dutasteride and bicalutamide as a cytoreductive regimen prior to permanent interstitial brachytherapy. American Brachytherapy Society Annual Meeting, Philadelphia, PA. May 10, 2006. Brachytherapy 2006; 5:108.

Merrick GS, Wallner KE, Butler WM, Galbreath RW, Allen ZA, Adamovich E, True L. Brachytherapy in Men ≤ 54 years of age with clinically localized prostate cancer. American Brachytherapy Society Annual Meeting, Philadelphia, PA. May 10, 2006. Brachytherapy 2006; 5:107.

Elliott, K, Wallner KE, Merrick GS, Herstein P. Medical malpractice claims in a prostate brachytherapy practice: causes and legal costs. American Brachytherapy Society Annual Meeting, Philadelphia, PA. May 10, 2006. Brachytherapy 2006; 5:116.

 

Gutman S, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Adamovich E. Temporal relationship between colorectal cancer and clinically localized prostate cancer in patients managed with permanent interstitial brachytherapy. American Brachytherapy Society Annual Meeting, Philadelphia, PA. May 12, 2006. Brachytherapy 2006; 5:93.

Grimm PD, Merrick GS, Butler WM, Blasko JC, Sylvester JE, Allen ZA, Chaudry U, Mazza A. Preliminary analysis of the ProQura multi-institutional prostate brachytherapy dosimetry database. American Brachytherapy Society Annual Meeting, Philadelphia, PA. May 12, 2006. Brachytherapy 2006; 5:91.

Butler WM, Merrick GS, Wallner KE. The meaning of prescription dose and D90 in permanent seed prostate brachytherapy. American Brachytherapy Society Annual Meeting, Philadelphia, PA. May 11, 2006. Brachytherapy 2006; 5:87.

Nurani RD, Wallner KE, Merrick GS, Orio PF, Virgin J, True L. The prognostic value of percent positive biopsies in intermediate to high risk prostate cancer treated with brachytherapy and supplemental beam radiotherapy. American Brachytherapy Society Annual Meeting, Philadelphia, PA. May 12, 2006. Brachytherapy 2006; 5:89.

Frank SJ, Blasko JC, Sylvester JE, Kuban DA, Moran BJ, Wallner KE, Vera R, Merrick GS, Zietman AL, Roach M, Clark D, Prestidge BR, Potters L, Michalski JM, Beyer DC, Lee WR, Stock RG, Davis BJ, Hurwitz MD, Grimm PD. Interstitial implant alone with or without external beam radiation therapy for intermediate risk localized prostate cancer: Patterns of Care Study in the United States. American Brachytherapy Society Annual Meeting, Philadelphia, PA. May 12, 2006. Brachytherapy 2006; 5:92.

 

Orio PF, Wallner KE, Merrick GS, Herstein A, Mitsuyama P, Thornton K, Butler WM, Sutlief S. Dosimetric parameters as predictive factors for biochemical control in higher risk prostate cancer patients treated with brachytherapy and supplemental beam radiation. American Brachytherapy Society Annual Meeting, Philadelphia, PA. May 10-12, 2006. Brachytherapy 2006; 5:111.

Herstein A, Wallner K, Merrick G, Orio P, True L, Butler W. Dosimetric parameters as predictive factors for biochemical control in low risk prostate cancer patients treated with I-125 or PD-103 brachytherapy. American Brachytherapy Society Annual Meeting, Philadelphia, PA. May 10-12, 2006. Brachytherapy 2006; 5:117.

Mitsuyama H, Wallner KE, Merrick GS, Virgin J, Orio PF, True L. The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd-103 plus beam radiation. American Brachytherapy Society Annual Meeting, Philadelphia, PA. May 10-12, 2006. Brachytherapy 2006; 5:117.

Nurani RD, Wallner KE, Merrick GS, Orio P, Virgin J, True L. The prognostic value of percent positive biopsies in intermediate to high risk prostate cancer treated with brachytherapy and supplemental beam radiotherapy. American Society of Clinical Oncology Annual Meeting, Atlanta, GA. June 2-6, 2006. JCO 2006; 24(18suppl):252s.

Sylvester J, Grimm P, Blasko J, Miller J, Orio P, Skoglund S, Galbreath R, Merrick G. 15-year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy: Seattle experience. American Society for Therapeutic Radiology and Oncology 48th Annual Meeting, Philadelphia, PA. November 5-9, 2006. Int J Radiat Oncol Biol Phys 2006; 66:3 (suppl):S58.

 

Lief J, Merrick GS, Butler W, Wallner K, Galbreath R, Allen Z. Long-term rectal function following permanent prostate brachytherapy. American Society for Therapeutic Radiology and Oncology 48th Annual Meeting, Philadelphia, PA. November 5-9, 2006. Int J Radiat Oncol Biol Phys 2006; 66:3 (suppl):S336.

Adamovich E, Merrick G, Gutman S, Butler W, Wallner K, Allen Z, Galbreath R, Lief J, Anderson R. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. American Society for Therapeutic Radiology and Oncology 48th Annual Meeting, Philadelphia, PA. November 5-9, 2006. Int J Radiat Oncol Biol Phys 2006; 66:3 (suppl):S357.

Allen Z, Merrick G, Butler W, Wallner K, Kurko B, Anderson R, Grammer R, Galbreath R, True L, Adamovich E. Extracapsular radiation dose annulus correlates with biochemical control in low-risk prostate brachytherapy patients: results of a prospective randomized trial. American Society for Therapeutic Radiology and Oncology 48th Annual Meeting, Philadelphia, PA. November 5-9, 2006. Int J Radiat Oncol Biol Phys 2006; 66:3 (suppl):S359.

Merrick G, Butler W, Wallner K, Galbreath R, Allen Z, Adamovich E. The impact of body mass index on cause-specific, biochemical and overall survival following permanent prostate brachytherapy. American Society for Therapeutic Radiology and Oncology 48th Annual Meeting, Philadelphia, PA. November 5-9, 2006. Int J Radiat Oncol Biol Phys 2006; 66:3 (suppl):S362. 

Galbreath R, Merrick G, Butler W, Wallner K, Allen Z, Adamovich E. The impact of primary Gleason pattern on survival following brachytherapy for Gleason score 7 prostate cancer. American Society for Therapeutic Radiology and Oncology 48th Annual Meeting, Philadelphia, PA. November 5-9, 2006. Int J Radiat Oncol Biol Phys 2006; 66:3 (suppl):S370.

Butler WM, Merrick G, Wallner K. Is D90 a radiobiologically sound endpoint for evaluation permanent seed prostate brachytherapy? American Society for Therapeutic Radiology and Oncology 48th Annual Meeting, Philadelphia, PA. November 5-9, 2006. Int J Radiat Oncol Biol Phys 2006; 66:3 (suppl):S372.

Kurko B, Merrick GS, Gutman S, Butler W, Wallner KE, Allen Z, Galbreath R, Lief J. Serial ultrasound-determined post-void residual urine volumes during external beam radiation therapy for clinically localized prostate cancer. American Society for Therapeutic Radiology and Oncology 48th Annual Meeting, Philadelphia, PA. November 5-9, 2006. Int J Radiat Oncol Biol Phys 2006; 66:3 (suppl):S383.

Grimm P, Merrick G, Butler W, Blasko J, Sylvester J, Allen Z, Chaudhry U, Mazza A. Initial analysis of ProQura: a multi-institutional database of prostate brachytherapy dosimetry. American Society for Therapeutic Radiology and Oncology 48th Annual Meeting, Philadelphia, PA. November 5-9, 2006. Int J Radiat Oncol Biol Phys 2006; 66:3 (suppl):S702.

Allen Z, Merrick G, Grimm P, Blasko J, Sylvester J, Butler W, Chaudhry U, Sitter M. Influence of Pro-Qura generated pre-plans on post-implant dosimetric quality: A review of a multi-institutional database. American Brachytherapy Society 28th Annual Meeting, Chicago, IL. April 29-May 1, 2007. Brachytherapy 2007; 6:100.

Merrick G, Galbreath R, Butler W, Wallner K, Allen Z, Adamovich E. Obesity is not predictive of overall survival following permanent prostate brachytherapy. American Brachytherapy Society 28th Annual Meeting, Chicago, IL. April 29-May 1, 2007. Brachytherapy 2007; 6:100-101.

Bittner N, Wallner KE, Merrick GS. The time gap between Pd-103 prostate brachytherapy and supplemental beam radiation does not impact on rectal morbidity or likelihood of cure. American Brachytherapy Society 28th Annual Meeting, Chicago, IL. April 29-May 1, 2007. Brachytherapy 2007; 6:101.

Niehaus A, Merrick G, Butler W, Wallner K, Allen Z, Galbreath R, Lief J. The role of trospium chloride in brachytherapy-related urinary morbidity. American Brachytherapy Society 28th Annual Meeting, Chicago, IL. April 29-May 1, 2007. Brachytherapy 2007; 6:101-102.

Grimm P, Merrick G, Blasko J, Sylvester J, Allen Z, Butler W, Chaudhry U, Sitter M. The relationship between isotope and learning curve in patients undergoing permanent prostate brachytherapy: Analysis of the Pro-Qura database. American Brachytherapy Society 28th Annual Meeting, Chicago, IL. April 29-May 1, 2007. Brachytherapy 2007; 6:102.

Gutman S, Merrick G, Butler W, Wallner K, Anderson R, Adamovich E, Allen Z, Galbreath R, Lief J. Urinary morbidity following transperineal template-guided prostate saturation biopsy. American Brachytherapy Society 28th Annual Meeting, Chicago, IL. April 29-May 1, 2007. Brachytherapy 2007; 6:108.

Merrick GS, Butler WM, Wallner KE, Galbreath R, Allen Z, Adamovich E, Lief J. Permanent prostate brachytherapy for high-risk prostate cancer. American Brachytherapy Society 28th Annual Meeting, Chicago, IL. April 29, 2007. Brachytherapy 2007; 6:78.

Grimm PD, Merrick GS, Blasko JC, Sylvester JE, Allen ZA, Butler WM, Chaudhry U, Sitter M. The effect of the time interval between brachytherapy and post-implant dosimetric evaluation on dosimetric quality: Analysis of the Pro-Qura database. American Brachytherapy Society 28th Annual Meeting, Chicago, IL. April 30, 2007. Brachytherapy 2007; 6:87.

Orio PE, Tudor I, Narayanan S, Cho P, Kim Y, Merrick GS, Wallner KE. Intraoperative TRUS-fluoroscopy fusion improves prostate brachytherapy quality. American Brachytherapy Society 28th Annual Meeting, Chicago, IL. April 30, 2007. Brachytherapy 2007; 6:87.

Merrick GS, Galbreath R, Butler WM, Wallner KE, Allen ZA, Adamovich E, Gutman S. The impact of primary Gleason pattern on survival following brachytherapy for Gleason 7 prostate cancer. American Brachytherapy Society 28th Annual Meeting, Chicago, IL. April 30, 2007. Brachytherapy 2007; 6:92.

Bittner N, Merrick GS, Lief J, Butler WM, Wallner KE, Allen ZA, Galbreath R. The impact of urinary storm on late urinary function following permanent prostate brachytherapy. American Brachytherapy Society 28th Annual Meeting, Chicago, IL. April 30, 2007. Brachytherapy 2007; 6:93.

Merrick GS, Gutman S, Adamovich E, Anderson R, Allen ZA, Butler WM, Wallner KE. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy: Implications for brachytherapy treatment planning. American Brachytherapy Society 28th Annual Meeting, Chicago, IL. April 30, 2007. Brachytherapy 2007; 6:93.

Bostancic C, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath R, Lief J, Gutman S. Isotope and patient age predict for PSA spikes following permanent prostate brachytherapy. American Brachytherapy Society 28th Annual Meeting, Chicago, IL. April 30, 2007. Brachytherapy 2007; 6:94.         

Allen ZA, Merrick GS, Butler WM, Wallner KE, Galbreath R, Adamovich E, Lief J. Androgen deprivation therapy does not impact cause-specific or overall survival in high risk prostate cancer treated with brachytherapy and supplemental external beam. American Society of Clinical Oncology Annual Meeting, Chicago, IL. June 1-5, 2007. JCO 2007; 25(18S):656s.

Bostancic C, Merrick GS, Butler W, Wallner K, Allen Z, Galbreath R, Lief J, Gutman S. Prediction of PSA spikes by isotope and patient age following permanent prostate brachytherapy. American Society of Clinical Oncology Annual Meeting, Chicago, IL. June 1-5, 2007. JCO 2007; 25(18S):652s.

Merrick GS, Gutman S, Adamovich E, Anderson R, Allen Z, Butler W, Wallner K. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy: implications for brachytherapy treatment planning. American Society of Clinical Oncology Annual Meeting, Chicago, IL. June 1-5, 2007. JCO 2007; 25(18S):652s.

Galbreath R, Merrick GS, Butler W, Wallner K, Allen Z, Adamovich A. Effect of obesity on overall survival  following permanent prostate brachytherapy. American Society of Clinical Oncology Annual Meeting, Chicago, IL. June 1-5, 2007. JCO 2007; 25(18S):655s.

Merrick GS, Galbreath R, Butler W, Wallner K, Allen Z, Brammer S, Moyad M. Patterns of death following permanent prostate brachytherapy. American Society for Therapeutic Radiology and Oncology 49th Annual Meeting, Los Angeles, CA. October 28 - November 1, 2007. Int J Radiat Oncol Biol Phys 2007; 69:3(suppl):S177.

Bittner N, Merrick GS, Wallner K, Lief J, Butler W, Allen Z, Galbreath R. The impact of urinary storm on late urinary function following permanent prostate brachytherapy.  American Society for Therapeutic Radiology and Oncology 49th Annual Meeting, Los Angeles, CA. October 28 - November 1, 2007. Int J Radiat Oncol Biol Phys 2007; 69:3(suppl):S634.

Allen Z, Merrick GS, Grimm P, Blasko J, Sylvester J, Butler W, Chaudhry U, Sitter M. The relationship between isotope and learning curve in patients undergoing permanent prostate brachytherapy: Analysis of the Pro-Qura database. American Society for Therapeutic Radiology and Oncology 49th Annual Meeting, Los Angeles, CA. October 28 - November 1, 2007. Int J Radiat Oncol Biol Phys 2007; 69:3(suppl):S357.

Niehaus A, Merrick GS, Bittner N, Butler W, Wallner K, Allen Z, Galbreath R, Lief J. The role of trospium chloride in brachytherapy-related detrusor overactivity. American Society for Therapeutic Radiology and Oncology 49th Annual Meeting, Los Angeles, CA. October 28 - November 1, 2007. Int J Radiat Oncol Biol Phys 2007; 69:3(suppl):S373.

Grimm P, Merrick GS, Blasko J, Sylvester J, Allen Z, Butler W, Chaudhry U, Sitter M. The effect of the time interval between brachytherapy and post-implant dosimetric evaluation on dosimetric quality: Analysis of the Pro-Qura database. American Society for Therapeutic Radiology and Oncology 49th Annual Meeting, Los Angeles, CA. October 28 - November 1, 2007. Int J Radiat Oncol Biol Phys 2007; 69:3(suppl):S330.

Brammer S, Merrick GS, Butler W, Wallner K, Anderson R, Adamovich E, Allen Z, Galbreath R, Lief J. The impact of needle trauma on urinary, bowel, and erectile function following transperineal template-guided prostate saturation biopsy: Implications for brachytherapy. American Society for Therapeutic Radiology and Oncology 49th Annual Meeting, Los Angeles, CA. October 28 - November 1, 2007. Int J Radiat Oncol Biol Phys 2007; 69:3(suppl):S350.

Mayadev, Merrick GS, Wallner K, Arthurs-Cutshall S, Bittner N. Dosimetric Parameters of rectal toxicity and fistula formation after prostate brachytherapy. American Society for Therapeutic Radiology and Oncology 49th Annual Meeting, Los Angeles, CA. October 28- November 1, 2007. Int J Radiat Oncol Biol Phys 2007; 69:3 (suppl):S313.

Butler WM, Merrick GS, Stewart R. Correlation between biochemical survival and radiobiological parameters in permanent prostate brachytherapy. 2008 World Congress of Brachytherapy, Boston, MA. May 4-6, 2008. Brachytherapy 2008; 7:114.

Merrick GS, Wallner KE, Butler WM, Galbreath RW, True L, Adamovich E. High quality brachytherapy dose distributions obviate the need for high-dose supplemental external beam radiation in patients with higher risk features: Results of a prospective randomized trial. 2008 World Congress of Brachytherapy, Boston, MA. May 4-6, 2008. Brachytherapy 2008; 7:114.

Bittner N, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Brammer SG. Patterns of death following permanent prostate brachytherapy. 2008 World Congress of Brachytherapy, Boston, MA. May 4-6, 2008. Brachytherapy 2008; 7:117.

Merrick GS, Wallner KE, Galbreath RW, Butler WM, Brammer SG, Allen ZA, Lief JH, Adamovich E. Biochemical and functional outcomes following brachytherapy in men ≤ 50 years of age with clinically localized prostate cancer. 2008 World Congress of Brachytherapy, Boston, MA. May 4-6, 2008. Brachytherapy 2008; 7:120.

Sylvester J, Merrick GS, Grimm P, Eulau S, Waheed M, Allen ZA, Butler WM. Influence of Pro-Qura feedback on rectal dosimetry following permanent prostate brachytherapy. 2008 World Congress of Brachytherapy, Boston, MA. May 4-6, 2008. Brachytherapy 2008; 7:121.

Brammer SG, Merrick GS, Wallner KE, Butler WM, Anderson RL, Allen ZA, Adamovich E. Pre-biopsy prostate-specific antigen velocity does not predict Gleason score, tumor location or cancer volume following transperineal template-guided prostate mapping biopsy. 2008 World Congress of Brachytherapy, Boston, MA. May 4-6, 2008. Brachytherapy 2008; 7:134.

Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Brammer SG, Lief JH. The impact of pretreatment serum testosterone on survival following permanent prostate brachytherapy. 2008 World Congress of Brachytherapy, Boston, MA. May 4-6, 2008. Brachytherapy 2008; 7:180.

Everly L, Merrick GS, Allen ZA, Butler WM, Wallner KE, Lief JH, Galbreath RW. Prostate cancer control and survival in Vietnam veterans exposed to Agent Orange. 2008 World Congress of Brachytherapy, Boston, MA. May 4-6, 2008. Brachytherapy 2008; 7:185.

Merrick GS, Wallner KE, Galbreath R, Butler WM, Brammer SG, Allen ZA, Adamovich E. Prostate brachytherapy in men ≥ 75 years of age. 2008 World Congress of Brachytherapy, Boston, MA. May 4-6, 2008. Brachytherapy 2008; 7:186.

Butler WM, Kurko BS, Murray BC, Merrick GS. Prostate gland motion in prone and supine positions assessed in real time by implanted electromagnetic transponders. American Society for Therapeutic Radiology and Oncology 50th Annual Meeting, Boston, MA. September 21-25, 2008. Int J Radiat Oncol Biol Phys 2008; 71:1 (suppl):S554.

Louiselle C, Merrick GS, Sylvester J, Grimm P, Eulau S, Waheed M, Allen ZA, Butler WM. Analysis of the Pro-Qura database: Implant quality, brachytherapist experience and rectal dose parameters. American Society for Therapeutic Radiology and Oncology 50th Annual Meeting, Boston, MA. September 21-25, 2008. Int J Radiat Oncol Biol Phys 2008; 71:1 (suppl):S326.

Orio P, Merrick GS, Allen ZA, Butler WM, Galbreath RW, Kurko B, Wallner KE. Influence of external beam radiation therapy on ultrasound determined post void residual urine volumes for clinically localized prostate cancer. American Society for Therapeutic Radiology and Oncology 50th Annual Meeting, Boston, MA. September 21-25, 2008. Int J Radiat Oncol Biol Phys 2008; 71:1 (suppl):S291.

Bittner N, Merrick GS, Wallner KE, Butler WM, Anderson RL, Allen ZA, Adamovich E. Pre-biopsy prostate-specific antigen velocity does not predict Gleason score, tumor location or cancer volume following transperineal-template guided prostate mapping biopsy: Implications for prostate brachytherapy treatment planning. American Society for Therapeutic Radiology and Oncology 50th Annual Meeting, Boston, MA. September 21-25, 2008. Int J Radiat Oncol Biol Phys 2008; 71:1 (suppl):S334.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Lief JH, Adamovich E. Pre-treatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy. American Society for Therapeutic Radiology and Oncology 50th Annual Meeting, Boston, MA. September 21-25, 2008. Int J Radiat Oncol Biol Phys 2008; 71:1 (suppl):S303.

Merrick GS, Galbreath RW, Butler WM, Wallner KE, Kurko BS, Anderson RL, Lief JH. Erectile function durability following permanent prostate brachytherapy. American Society for Therapeutic Radiology and Oncology 50th Annual Meeting, Boston, MA. September 21-25, 2008. Int J Radiat Oncol Biol Phys 2008; 71:1 (suppl):S549.

Galbreath RW, Merrick GS, Wallner KE, Butler WM, Allen ZA, Lief JH, Adamovich E. Biochemical and functional outcomes following brachytherapy in men ≤ 50 years of age with clinically organ-confined prostate cancer. American Society for Therapeutic Radiology and Oncology 50th Annual Meeting, Boston, MA. September 21-25, 2008. Int J Radiat Oncol Biol Phys 2008; 71:1 (suppl):S285.

Everly L, Merrick GS, Allen ZA, Butler WM, Wallner KE, Leif JH, Galberath RW, Adamovich E. Prostate cancer control and survival in Vietnam veterans exposed to Agent Orange. American Society for Therapeutic Radiology and Oncology 50th Annual Meeting, Boston, MA. September 21-25, 2008. Int J Radiat Oncol Biol Phys 2008; 71:1 (suppl):S340.

Merrick GS, Taira AV, Galbreath RW, Butler WM, Wallner KE, Kurko BS, Anderson R, Lief JH. Erectile function durability following permanent prostate brachytherapy. 2009 Genitourinary Cancers Symposium. Orlando Florida. Poster presentation. February 26-28, 2009.

Bittner N, Merrick GS, Wallner KE, Butler WM, Galbreath RW, Adamovich E. Whole pelvic radiotherapy in combination with transperineal interstitial brachytherapy: Does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer? American Brachytherapy Society annual meeting. Toronto, ON. May 31, 2009-June 2, 2009. Brachytherapy 2009; 8:110.

Mayadev J, Merrick GS, Reed J, Butler WM, Allen ZA, Wallner KE. Permanent prostate brachytherapy in prostate glands less than 20cm3. American Brachytherapy Society annual meeting. Toronto, ON. May 31, 2009-June 2, 2009. Brachytherapy 2009; 8:119.

Merrick GS, Allen ZA, Sylvester J, Grimm P, Butler WM, Khanjian J. Post-implant rectal dosimetry is not dependent on Pd-103 or I-125 seed activity. American Brachytherapy Society annual meeting. Toronto, ON. May 31, 2009-June 2, 2009. Brachytherapy 2009; 8:125.

Fang LC, Merrick GS, Murray BC, Wallner KE, Butler WM, Galbreath RL. The role of androgen deprivation therapy in high-risk prostate cancer with Gleason score 8-10 and prostate-specific antigen <15 treated with permanent interstitial brachytherapy. American Brachytherapy Society annual meeting. Toronto, ON. May 31, 2009-June 2, 2009. Brachytherapy 2009; 8:165.

Merrick GS, Butler WM, Galbreath RW, Wallner KE, Allen ZA, Reed J. Factors predicting prostate gland shrinkage following neoadjuvant cytoreductive therapy. American Brachytherapy Society annual meeting. Toronto, ON. May 31, 2009-June 2, 2009. Brachytherapy 2009; 8:165.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE. Factors impacting all cause mortality in men receiving androgen deprivation therapy with prostate brachytherapy. American Brachytherapy Society annual meeting. Toronto, ON. May 31, 2009-June 2, 2009. Brachytherapy 2009; 8:165.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Kurko BS, Anderson R, Lief JH. Erectile function durability following permanent prostate brachytherapy. American Brachytherapy Society annual meeting. Toronto, ON. May 31, 2009-June 2, 2009. Brachytherapy 2009; 8:168.

Allen ZA, Merrick GS, Stewart R, Butler WM, Reed J, Anderson RL, Adamovich E. Obesity does not predict Gleason score, tumor location or cancer volume following transperineal template-guided prostate mapping biopsy. American Brachytherapy Society annual meeting. Toronto, ON. May 31, 2009-June 2, 2009. Brachytherapy 2009; 8:173.

Sylvester JE, Grimm PD, Wong J, Lief JH, Khanjian JA, Merrick GS. Prostate brachytherapy biochemical relapse-free survival outcomes in intermediate-risk prostate cancer patients. American Brachytherapy Society annual meeting. Toronto, ON. May 31, 2009-June 2, 2009. Brachytherapy 2009; 8:176.

Merrick GS, Taira A, Galbreath RW, Butler WM, Allen AZ, Adamovich E, Wallner KE. Distribution of cancer foci identified with transperineal template guided biopsies: Implications for focal and other prostate cancer definitive treatment. American Society for Therapeutic Radiology and Oncology Annual Meeting, Chicago, IL. (Poster discussion) November 1-5, 2009. Int J Radiat Oncol Biol Phys 2009; 75:S152-S153.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Adamovich E, Wallner KE. Factors impacting all cause mortality in men receiving androgen deprivation therapy with prostate brachytherapy. American Society for Therapeutic Radiology and Oncology Annual Meeting, Chicago, IL. (Poster discussion) November 1-5, 2009. Int J Radiat Oncol Biol Phys 2009; 75:S154.

King BL, Butler WM, Reed JL, Murray BC, Kurko BS, Wallner KE, Merrick GS. Electromagnetic transponders indicate prostate size fluctuation during the course of external beam radiation therapy. American Society for Therapeutic Radiology and Oncology Annual Meeting, Chicago, IL. November 1-5, 2009. Int J Radiat Oncol Biol Phys 2009; 75:S331-S332.

Anderson R, Merrick GS, Butler WM, Galbreath RW, Wallner KE, Allen ZA. Factors predicting prostate gland shrinkage following neoadjuvent cytoreductive therapy. American Society for Therapeutic Radiology and Oncology Annual Meeting, Chicago, IL. November 1-5, 2009. Int J Radiat Oncol Biol Phys 2009; 75:S347.

Butler WM, Reed JL, Murray BC, Kurko BS, Wallner KE, Merrick GS. Comparison of the effect of prone versus supine patient immobilization on intrafraction prostate displacement monitored by real-time electromagnetic tracking. American Society for Therapeutic Radiology and Oncology Annual Meeting, Chicago, IL. November 1-5, 2009. Int J Radiat Oncol Biol Phys 2009; 75:S356.

Bittner NH, Merrick GS, Stewart R, Allen ZA, Butler WM, Wallner KE. Obesity does not correlate with adverse pathologic findings on transperineal template-guided mapping biopsy of the prostate. American Society for Therapeutic Radiology and Oncology Annual Meeting, Chicago, IL. November 1-5, 2009. Int J Radiat Oncol Biol Phys 2009; 75:S303.

Fang LC, Merrick GS, Murray BC, Butler WM, Wallner KE, Galbreath RW. The role of androgen deprivation therapy in high risk prostate cancer with gleason score 8-10 and PSA ≤ 15ng/mL treated with permanent interstitial brachytherapy. American Society for Therapeutic Radiology and Oncology Annual Meeting, Chicago, IL. November 1-5, 2009. Int J Radiat Oncol Biol Phys 2009; 75:S338.

Bittner N, Butler WM, Reed JL, Murray BC, Kurko BS, Wallner KE, Merrick GS. Electromagnetic tracking of intrafraction prostate displacement among patients externally immobilized in the prone position. American Society for Therapeutic Radiology and Oncology Annual Meeting, Chicago, IL. November 1-5, 2009. Int J Radiat Oncol Biol Phys 2009; 75:S328.

Mayadev J, Merrick GS, Reed JL, Butler WM, Wallner KE. Permanent prostate brachytherapy in prostate glands less than 20cm3. American Society for Therapeutic Radiology and Oncology Annual Meeting, Chicago, IL. November 1-5, 2009. Int J Radiat Oncol Biol Phys 2009; 75:S315.

Khanjian JA, Merrick GS, Allen ZA, Sylvester J, Grimm PO, Murray BC, Kurko BS, Butler WM. Influence of Pro-Qura on post-implant dosimetric quality among low, intermediate and high volume prostate brachytherapists. American Society for Therapeutic Radiology and Oncology Annual Meeting, Chicago, IL. November 1-5, 2009. Int J Radiat Oncol Biol Phys 2009; 75:S327.

Allen ZA, Merrick GS, Sylvester J, Grimm PO, Butler WM, Reed JL, Khanjian J. Post-implant rectal dosimetry is not dependent on Pd-103 or I-125 seed activity. American Society for Therapeutic Radiology and Oncology Annual Meeting, Chicago, IL. November 1-5, 2009. Int J Radiat Oncol Biol Phys 2009; 75:S321-322.

Reed JL, Merrick GS, Butler WM, Allen ZA, Kurko BS, Murray BC, Galbreath RW. PSA kinetics following high dose intensity modulated external beam radiation therapy with and without image guidance. American Society for Therapeutic Radiology and Oncology Annual Meeting, Chicago, IL. November 1-5, 2009. Int J Radiat Oncol Biol Phys 2009; 75:S332.

Sylvester JE, Grimm PD, Wong J, Galbreath RW, Khanjian JA, Merrick GS, Blasko JC. 15-year biochemical relapse-free survival and overall survival following I125 prostate brachytherapy in clinically localized prostate cancer: Seattle Experience. American Society for Therapeutic Radiology and Oncology Annual Meeting, Chicago, IL. November 1-5, 2009. Int J Radiat Oncol Biol Phys 2009; 75:S326-S327.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Allen ZA, Wallner KE. Relationship between Prebrachytherapy Erectile Function, Age and Overall Survival. American Brachytherapy Society Annual Meeting, Atlanta, GA. April 29 ,2010 - May 1, 2010. Brachytherapy 2010; 9:S54-S55.

Merrick GS, Butler WM, Taira AV,Galbreath RW, Lief JH, Allen ZA, Wallner KE. Serum Testosterone Changes in Patients with a PSA Spike Following Prostate Brachytherapy.  American Brachytherapy Society Annual Meeting, Atlanta, GA. April 29, 2010 - May 1, 2010. Brachytherapy 2010; 9:S29.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Wallner KE, Adamovich E. The Impact of Diabetes Mellitus on Survival in Men with Clinically Localized Prostate Cancer Treated with Permanent Interstitial Brachytherapy. American Brachytherapy Society Annual Meeting, Atlanta, GA. April 29, 2010 - May 1, 2010. Brachytherapy 2010; 9:S77-S78.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Allen ZA, Wallner KE, Adamovich E. Prostate Cancer Death is Unlikely in High-Risk Patients Following High-Quality Brachytherapy. American Brachytherapy Society Annual Meeting, Atlanta, GA. April 29, 2010 - May 1, 2010. Brachytherapy 2010; 9:S54.

Merrick GS, Butler WM, Taira AV, Galbreath RW, Lief JH, Allen ZA, Wallner KE. Serum Testosterone Kinetics following Brachytherapy for Clinically Localized Prostate Cancer. American Brachytherapy Society Annual Meeting, Atlanta, GA. April 29, 2010 - May 1, 2010. Brachytherapy 2010; 9:S28.

Bittner N, Merrick GS, Galbreath RW, Butler WM, Adamovich E, Wallner KE. Extended Biopsy is Associated with Improved Biochemical Control in Patients Treated with Permanent Prostate Brachytherapy. American Brachytherapy Society Annual Meeting, Atlanta, GA. April 29, 2010 - May 1, 2010. Brachytherapy 2010; 9:S74.

Taira AV, Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E, Wallner KE. Long-Term Outcome for Clinically Localized Prostate Cancer Treated with Permanent Interstitial Brachytherapy. American Brachytherapy Society Annual Meeting, Atlanta, GA. April 29, 2010 - May 1, 2010. Brachytherapy 2010; 9:S25.

Bittner N, Merrick GS, Butler WM, Galbreath RW, Anderson RA, Allen ZA, Wallner KE. Pre-treatment Prostate Cancer Volume and Biopsy Gleason Score Predicts Prostate Gland and Transition Zone Shrinkage following Neoadjuvant Cytoreductive Therapy. American Brachytherapy Society Annual Meeting, Atlanta, GA. April 29, 2010 - May 1, 2010. Brachytherapy 2010; 9:S100.

Fang LC, Merrick GS, Murray B, Wallner KE, Butler WM, Galbreath RW. Androgen Deprivation Therapy in High-Risk Prostate Cancer with Gleason Score 8-10 and PSA ≤ 15 Treated with Permanent Interstitial Brachytherapy. American Brachytherapy Society Annual Meeting, Atlanta, GA. April 29, 2010 - May 1, 2010. Brachytherapy 2010; 9:S54.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Lief JH, Wallner KE. Relationship Between Prostate Cancer Mortality and Number of Unfavorable Risk Factors Following Brachytherapy. American Brachytherapy Society Annual Meeting, Atlanta, GA. April 29, 2010 - May 1, 2010. Brachytherapy 2010; 9:S30.

home
about
our people
scientific publications
research resources
patient resources
news
special projects
doante
contact us
wheeling hospital